Open Access

Expression of miR-30c and miR-29b in prostate cancer and its diagnostic significance

  • Authors:
    • Chuanan Zhu
    • Xiumei Hou
    • Jiabin Zhu
    • Chunxiao Jiang
    • Wei Wei
  • View Affiliations

  • Published online on: June 21, 2018     https://doi.org/10.3892/ol.2018.9007
  • Pages: 3140-3144
  • Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This study aimed to investigate the expression of miR-30c and miR-29b in prostate cancer (PCa) and its clinical significance. The expression of miR-30c and miR-29b was detected by RT-qPCR in 187 cases of PCa and their adjacent tissues. Combined with clinical information, the correlation between the expression of miR-29b and miR-30c and the clinical features of PCa was analyzed, and ROC curve was plotted. The expression of miR-30c and miR-29b detected by RT-qPCR showed that the expression of miR-29b and miR-30c in PCa tissues was significantly lower than that in adjacent cancerous tissues (p<0.05). By comparing the expression and clinical data of miR-29b and miR-30c in the cancer tissues of PCa patients, it was observed that age, smoking, and TNM staging were not related to miR-29b and miR-30c expression (p>0.05), while lymph node metastasis, bone metastasis, and Gleason score were related to the expression of miR-29b and miR-30c (p<0.01). The ROC curve showed that miR-29b AUC, 0.924; 95% CI, 0.824-0.967, and miR-30c AUC, 0.944; 95% CI, 0.798-0.972. miR-30c and miR-29b are clinically relevant to PCa. In conclusion, detecting the expression of miR-30c and miR-29b not only can differentiate between PCa and paracancerous tissues, but it is also anticipated to become a new biomarker for the diagnosis of PCa.
View Figures
View References

Related Articles

Journal Cover

September-2018
Volume 16 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu C, Hou X, Zhu J, Jiang C and Wei W: Expression of miR-30c and miR-29b in prostate cancer and its diagnostic significance. Oncol Lett 16: 3140-3144, 2018
APA
Zhu, C., Hou, X., Zhu, J., Jiang, C., & Wei, W. (2018). Expression of miR-30c and miR-29b in prostate cancer and its diagnostic significance. Oncology Letters, 16, 3140-3144. https://doi.org/10.3892/ol.2018.9007
MLA
Zhu, C., Hou, X., Zhu, J., Jiang, C., Wei, W."Expression of miR-30c and miR-29b in prostate cancer and its diagnostic significance". Oncology Letters 16.3 (2018): 3140-3144.
Chicago
Zhu, C., Hou, X., Zhu, J., Jiang, C., Wei, W."Expression of miR-30c and miR-29b in prostate cancer and its diagnostic significance". Oncology Letters 16, no. 3 (2018): 3140-3144. https://doi.org/10.3892/ol.2018.9007